RT Journal Article
SR Electronic
T1 Evaluating the effectiveness of rapid SARS-CoV-2 genome sequencing in supporting infection control teams: the COG-UK hospital-onset COVID-19 infection study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.10.22270799
DO 10.1101/2022.02.10.22270799
A1 Oliver Stirrup
A1 James Blackstone
A1 Fiona Mapp
A1 Alyson MacNeil
A1 Monica Panca
A1 Alison Holmes
A1 Nicholas Machin
A1 Gee Yen Shin
A1 Tabitha Mahungu
A1 Kordo Saeed
A1 Tranprit Saluja
A1 Yusri Taha
A1 Nikunj Mahida
A1 Cassie Pope
A1 Anu Chawla
A1 Maria-Teresa Cutino-Moguel
A1 Asif Tamuri
A1 Rachel Williams
A1 Alistair Darby
A1 David Robertson
A1 Flavia Flaviani
A1 Eleni Nastouli
A1 Samuel Robson
A1 Darren Smith
A1 Matthew Loose
A1 Kenneth Laing
A1 Irene Monahan
A1 Beatrix Kele
A1 Sam Haldenby
A1 Ryan George
A1 Matthew Bashton
A1 Adam Witney
A1 Matthew Byott
A1 Francesc Coll
A1 Michael Chapman
A1 Sharon Peacock
A1 COG-UK HOCI Investigators
A1 The COVID-19 Genomics UK (COG-UK) consortium
A1 Joseph Hughes
A1 Gaia Nebbia
A1 David G Partridge
A1 Matthew Parker
A1 James Price
A1 Christine Peters
A1 Sunando Roy
A1 Luke B Snell
A1 Thushan I de Silva
A1 Emma Thomson
A1 Paul Flowers
A1 Andrew Copas
A1 Judith Breuer
YR 2022
UL http://medrxiv.org/content/early/2022/02/13/2022.02.10.22270799.abstract
AB Introduction Viral sequencing of SARS-CoV-2 has been used for outbreak investigation, but there is limited evidence supporting routine use for infection prevention and control (IPC) within hospital settings.Methods We conducted a prospective non-randomised trial of sequencing at 14 acute UK hospital trusts. Sites each had a 4-week baseline data-collection period, followed by intervention periods comprising 8 weeks of ‘rapid’ (<48h) and 4 weeks of ‘longer-turnaround’ (5-10 day) sequencing using a sequence reporting tool (SRT). Data were collected on all hospital onset COVID-19 infections (HOCIs; detected ≥48h from admission). The impact of the sequencing intervention on IPC knowledge and actions, and on incidence of probable/definite hospital-acquired infections (HAIs) was evaluated.Results A total of 2170 HOCI cases were recorded from October 2020-April 2021, with sequence reports returned for 650/1320 (49.2%) during intervention phases. We did not detect a statistically significant change in weekly incidence of HAIs in longer-turnaround (IRR 1.60, 95%CI 0.85-3.01; P=0.14) or rapid (0.85, 0.48-1.50; P=0.54) intervention phases compared to baseline phase. However, IPC practice was changed in 7.8% and 7.4% of all HOCI cases in rapid and longer-turnaround phases, respectively, and 17.2% and 11.6% of cases where the report was returned. In a per-protocol sensitivity analysis there was an impact on IPC actions in 20.7% of HOCI cases when the SRT report was returned within 5 days.Conclusion While we did not demonstrate a direct impact of sequencing on the incidence of nosocomial transmission, our results suggest that sequencing can inform IPC response to HOCIs, particularly when returned within 5 days.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04405934Clinical Protocols https://www.medrxiv.org/content/10.1101/2021.04.13.21255342v1 Funding StatementCOG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NHS HRA gave ethical approval for this work (ref: REC 20/EE/0118).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFully anonymised versions of the datasets generated and analysed during the current study will be stored on a data repository and sharing platform CSDR (https://clinicalstudydatarequest.com/) so that the data may be reused by other researchers. This will include individual participant level data, data dictionaries and the statistical analysis plan for this study. This will be done within 6 months of public reporting of results. Access through the data sharing platform requires submission of a viable research plan for review.